KainosMed Signs Patent Transfer Agreement for KM-819 with Korea Research Institute of Chemical Technology

[Asia Economy Reporter Hyunseok Yoo] Kainosmed recently announced on the 11th that it has signed a contract to transfer the patent rights of KM-819, a candidate drug for brain disease treatment, from the Korea Research Institute of Chemical Technology.

The patent rights for KM-819 were filed and owned by the Korea Research Institute of Chemical Technology, and Kainosmed had an exclusive license after receiving a technology transfer from the institute in 2015. Through this contract, Kainosmed has now acquired the patent rights for KM-819.

At the end of last year, Kainosmed received approval for Phase 2 clinical trial plans for Parkinson's disease from the US FDA (Food and Drug Administration) and for multiple system atrophy (MSA) from the Korean Ministry of Food and Drug Safety, and has begun full-scale clinical development.

A Kainosmed official stated, "The patent rights transfer contract has already been completed and the transfer procedures have begun," adding, "As the patent rights owner, Kainosmed is now in a favorable position for future technology transfers."

In addition, Kainosmed has filed two other patents, including a use patent for KM-819.

This content was produced with the assistance of AI translation services.